Clostridium difficile is the causative pathogen of antibioticassociated diarrhea and pseudomembranous colitis (10, 14). It produces two major protein toxins (toxins A and B), which are the prototypes of the family of large clostridial cytotoxins. Both toxins inhibit the functions of Rho GTPases by monoglucosylation. Beside toxins A and B, some strains of C. difficile produce a binary ADP-ribosylating toxin (CDT) which modifies actin (22). The pathogenic role of CDT in diseases induced by C. difficile is not clear, but about 6 to 12.5% of strains isolated from patients with enteritis contained CDT genes (20, 26) .
ing components and the enzymatic components of C2 toxin and the toxins of the iota subfamily was observed (12, 21) .
Here we studied the enzyme component of CDT and characterized its enzyme activity. We show that the N-terminal part of CDTa is responsible for interaction with the binding component, whereas the C-terminal part harbors transferase activity. For delivery of CDTa into cells we used the Ib binding and translocation component from iota toxin, because CDTb was not expressed as a recombinant protein in Escherichia coli. Recently, we characterized the catalytic center of the ADPribosyltransferase C2I and identified several amino acid residues essential for the transferase activity (8) . Here we studied the functional roles of several amino acid residues of CDTa suggested to be conserved among the actin ADP-ribosylating toxins. Moreover, we compared the minimal structural requirements of CDTa with those of the enzyme components of iota toxin (Ia) and C2 toxin (C2I).
MATERIALS AND METHODS

Materials.
Cell culture medium was purchased from Biochrom (Berlin, Germany), fetal calf serum was purchased from PAN Systems (Aidenbach, Germany), and cell culture materials were purchased from Falcon (Heidelberg, Germany). Platelet cytosol was prepared as described previously (23) . G-actin from rabbit skeletal muscle was prepared as described previously (17) . The binding component (Ib) from Clostridium perfringens iota toxin was purified and activated with chymotrypsin as described previously (9) . Protein A coupled to peroxidase and the enhanced chemiluminescence detection kit were from Amersham (Braunschweig, Germany). The nitrocellulose blotting membrane was obtained from Schleicher and Schuell (Dassel, Germany). The molecular weight protein marker was from Bio-Rad (Hercules, Calif.). Oligonucleotides were purchased from MWG (Ebersberg, Germany), the pGEX2T vector (included in the glutathione S-transferase [GST] Gene Fusion System) and glutathione Sepharose 4B were obtained from Pharmacia Biotech (Uppsala, Sweden), the DNA molecular weight marker (lambda HindIII) and restriction enzymes were from Roche Diagnostics (Mannheim, Germany), and T4 ligase and competent E. coli cells were from Stratagene (Heidelberg, Germany). The Topo-TA-Cloning kit was from Invitrogen (Groningen, The Netherlands). Taq polymerase was purchased from Roche Diagnostics. The JETsorb DNA extraction kit was from Genomed GmbH (Bad Oeynhausen, Germany). PCR was performed in the Gene Amp PCR System 2400 from Perkin-Elmer (Langen, Germany), and DNA sequencing was done with the Cycle Sequencing Ready Reaction Kit (ABI PRISM) from Perkin-Elmer. Thrombin and phalloidin-rhodamine were obtained from Sigma (Deisenhofen, Germany). [
32 P]NAD (30 Ci/mmol) was purchased from DuPont NEN (Bad Homburg, Germany).
Construction of CDTa. For construction of pGEX2T-CDTa, the translated region of CDTa (1,393 bp) was amplified by PCR using genomic DNA from C. difficile strain 75 (a clinical isolate from a patient with an unusual extragastrointestinal C. difficile infection of the hip; kindly provided by Gisela Schallehn, Bonn, Germany) as a template. PCR was performed using the primer pair CDTAs (5Ј-GGATCCATGAAAAAATTTAGGAAAC-3Ј) and CDTAa (5Ј-GA ATTCTTAAGGTATCAATGTTGC-3Ј). Amplification was performed by denaturation at 94°C for 10 s, primer annealing at 48°C for 30 s, and extension at 68°C for 3.5 min, which was repeated for 30 cycles. The PCR product (2 l) was cloned into the Topo cloning vector pCR2.1 (Invitrogen) and transformed into E. coli TOP10 FЈcells according to the manufacturer's instructions. The plasmid was isolated and digested with BamHI-EcoRI for mobilization of CDTa. After separation on a 1% agarose gel, the bands were excised and extracted using the JETsorb DNA extraction kit (Genomed) according to the manufacturer's instructions and further subcloned in the BamHI-EcoRI-digested pGEX2T plasmid.
Construction of CDTa mutants. The CDTa mutants were constructed by site-directed mutagenesis, using the pGEX2T-CDTa plasmid as a template and the respective oligonucleotides. The Quikchange kit was used according to the manufacturer's instructions. For each mutant, two complementary synthetic oligonucleotides were needed (only one of the two complementary oligonucleotides is indicated): R345K, 5Ј-CT AAT TTA ACT GTA TAT AAA AGA TCT GGT  CCT CAA G-3Ј; R346K, 5Ј-CT GTA TAT AGA AAA TCT GGT CCT CAA  GAA TTT GG-3Ј; S388A, 5Ј-GCA CTG TCT TAT CCA AAC TTT ATT GCT  ACT AGT ATT GGT AGT GTG-3Ј; T389V, 5Ј-CCA AAC TTT ATT AGT  GTT AGT ATT GGT AGT GTG-3Ј; S390A, 5Ј-CCA AAC TTT ATT AGT  ACT GCT ATT GGT AGT GTG AAT ATG AGT GC-3Ј; E428Q, 5Ј-CCA  GGT TAT GCA GGT CAA TAT GAA GTG CTT TTA AAT CAT GG-3Ј; and  E430Q, 5Ј-GGT TAT GCA GGT GAA TAT CAA GTG CTT TTA AAT CAT  GG-3Ј . The mutated plasmids were transformed into E. coli TG1 pACYC-IRL 10 competent cells (Promega Corporation), and the respective mutations were confirmed by DNA sequencing.
Construction of CDTa 244-463 and CDTa 1-240 . CDTa 1-240 was amplified from chromosomal DNA of C. difficile strain 75 with Taq polymerase (Roche Diagnostics) and the oligonucleotide primers CdribAs (5Ј-GGA TCC ATG AAA AAA TTT AGG AAA C-3Ј) and CDTa240a-BamHI (5Ј-GGA TCC AAT TTT ATC TAT TTT TAT AC-3Ј), both containing a BamHI site. Amplification was performed by denaturation at 94°C for 10 s, primer annealing at 48°C for 30 s, and extension at 68°C for 1 min, which was repeated for 25 cycles. The resulting PCR product (4 l) was cloned into the Topo cloning vector pCR2.1 and transformed into E. coli TOP10FЈ cells according to the manufacturer's instructions. The plasmids were isolated, digested with BamHI, and separated on a 1% agarose gel. The CDTa 1-240 band was excised and extracted, using the JETsorb DNA extraction kit (Genomed) according to the manufacturer's instructions, and cloned into the BamHI-digested pGEX2T plasmid. CDTa 244-463 was amplified from plasmid pGEX2T-CDTa with Taq polymerase and the oligonucleotide primers CDTA244s-BamHI (5Ј-GGA TCC GTT ATA GAT GGG AAG CAC-3Ј) and CdribAa (5Ј-GAA TTC TTA AGG TAT CAA TGT TGC-3Ј). Amplification was performed by denaturation at 94°C for 10 s, primer annealing at 52°C for 30 s, and extension at 68°C for 1 min, which was repeated for 25 cycles. The resulting PCR product (4 l) was cloned into the Topo cloning vector pCR2.1 and transformed into E. coli TOP10FЈ cells according to the manufacturer's instructions. The plasmids were isolated, digested with BamHI-EcoRI, and separated on a 1% agarose gel. The CDTa 244-463 band was extracted with the JETsorb kit according to the manufacturer's instructions and cloned into the BamHI-EcoRI-digested pGEX2T plasmid.
Construction of N-terminally truncated C2I and iota toxin a. Truncations of the enzyme components C2I and iota toxin a were obtained by PCR using the pGEX-2T-C2I and pGEX-2T-Ia plasmids, respectively, as templates with the following primers. The 5Ј primers harbor a BglII restriction site (underlined), as follows: C2I , AGA TCT GAA CTA GAC TCT AAA GTA AAT AAC. The 3Ј primer for the C2I constructs contains a BglII site (underlined): AGA TCT CTA AAT CTC TTT ATT TTG TAT AC. The 3Ј primer for iota toxin a truncations has a BamHI site (underlined): GGA TCC TTA ATT TAT CAA TGT TGC ATC CAA. The PCR program was as follows: denaturation for 1 min at 94°C; 25 cycles of denaturation for 10 s at 94°C, annealing at 30 s at 51°C for pGEX-2T-C2I or at 50°C for pGEX-2T-Ia, and elongation with Taq polymerase for 1 min at 68°C; and a final elongation for 10 min at 68°C. The PCR products were cloned into the pCR2.1 vector. The fragments containing C2I truncations were excised by digestion with BglII. For iota toxin a truncations, a double digest with BglII and BamHI was performed. Subsequently, the DNA was ligated into a BamHI-digested and dephosphorylated pGEX-2T plasmid. The correct orientation of the insert was confirmed by sequencing.
Expression and purification of recombinant proteins. Recombinant wild-type CDTa (rCDTa) or various CDTa mutant proteins were expressed as recombinant GST fusion proteins in E. coli TG1 cells. Bacteria were grown at 37°C in Luria-Bertani medium containing 100 g of ampicillin per ml and 25 g of chloramphenicol per ml to an optical density (at 600 nm) of 0.8. At this time, IPTG (isopropyl-␤-D-thiogalactopyranoside) was added to a final concentration of 0.1 mM. The cultures were incubated at 29°C for another 24 h. Bacteria were sedimented at 7,000 ϫ g (10 min, 4°C) and resuspended in lysis buffer (10 mM NaCl, 20 mM Tris [pH 7.4], and 1% Triton X-100). The GST fusion proteins were cleaved directly from the beads with thrombin, and the proteins were stored in phosphate buffer containing 0.5% Tween 20 and 0.5% Triton X-100. C2I-C and Ia-C proteins were expressed in E. coli. The proteins were purified as described in detail elsewhere (8) .
SDS-PAGE and immunoblotting. Sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) was performed according to the methods of Laemmli (15) . The gels were stained with Coomassie brilliant blue R-250. The amounts of the CDTa proteins were determined by Coomassie blue staining. Immunoblot analysis was done with an antiserum against C. spiroforme toxin as described previously (7).
ADP-ribosylation assay. In vitro [ 32 P]ADP-ribosylation of ␤/␥-nonmuscle actin was performed with platelet cytosol (50 g of protein) as the substrate and the various toxins as described previously (8) . For [ 32 P]ADP-ribosylation of ␣-actin, purified rabbit skeletal muscle actin (1 g) was incubated with [ 32 P]NAD and the various toxins at 37°C. Proteins were subjected to SDS-12.5% PAGE, and radiolabeled actin was visualized by phosphorimaging. For in vitro [
32 P]ADPribosylation of lysate proteins from Vero cells, cells were lysed and 50 g of lysate protein was incubated for 15 min at 37°C in the presence of [ 32 P]NAD. Cell culture and cytotoxicity assays. Vero cells were cultivated in tissue culture flasks at 37°C and 5% CO 2 in Dulbecco's modified Eagle's medium containing 5% heat-inactivated (30 min, 56°C) fetal calf serum, 2 mM L-glutamate, 100 U of penicillin per ml, and 100 g of streptomycin per ml. Cells were routinely trypsinized and reseeded twice a week. For cytotoxicity assays, Vero cells were grown as subconfluent monolayers in 12-well plates and treated with chymotrypsin-activated Ib together with rCDTa or the mutant CDTa protein in complete medium. For competition assays, subconfluent Vero cells were incubated with Ib plus CDTa together with a 400-fold excess of CDTa .
RESULTS
Cloning and characterization of rCDTa and CDTa mutants. The CDTa gene was amplified from C. difficile strain 75 and ligated into the pGEX plasmid for expression of GST fusion proteins in E. coli. The purified rCDTa was analyzed by SDS-PAGE. The Coomassie blue-stained protein is shown in Fig. 1 . rCDTa activity was tested in an in vitro ADP-ribosylation assay with [
32 P]NAD and ␤/␥-actin from platelet cytosol or ␣-actin purified from rabbit skeletal muscle as the substrate. As shown in Fig. 1 , rCDTa caused the ADP-ribosylation of platelet actin and of skeletal muscle actin, indicating the same substrate specificity as for iota toxin (11) .
Sequence comparison of CDTa with the C2I ADP-ribosyltransferase from C. botulinum revealed the positions of the highly conserved amino acid residues in CDTa suggested to be involved in NAD-binding and/or enzyme activity ( Fig. 2A) . Site-directed mutagenesis was performed with the pGEXCDTa plasmid as a template, and mutations were confirmed by sequencing. Figure 2B summarizes the sequences of mutated CDTa proteins. Proteins were expressed in E. coli and cleaved with thrombin to remove the GST part. The purified CDTa proteins were subjected to SDS-PAGE, and the stained gel is shown in Fig. 3A . Furthermore, CDTa proteins were analyzed by immunoblot analysis with an antibody raised against the C. spiroforme ADP-ribosyltransferase, which is immunologically related to CDTa (20) (Fig. 3B) . CDTa and the mutant proteins were recognized by the antibody, showing the expected molecular mass of Ϸ48 kDa. This antibody did not recognize E. coli proteins and showed no cross-reaction with C2I transferase from C. botulinum (not shown). The lower migrating band was present in all preparations of recombinant CDTa proteins and most likely represents a degradation product.
In vitro ADP-ribosyltransferase activity of CDTa mutants. We tested the ADP-ribosyltransferase activities of rCDTa and mutant CDTa in an in vitro ADP-ribosylation assay with [ 32 P]NAD and either platelet cytosol actin or rabbit skeletal muscle actin as a substrate. The autoradiogram of [ 32 P]ADPribosylated actin is shown in Fig. 4 . Because rCDTa and the CDTa mutant proteins T389V, S390A, and R346K labeled actin from platelet cytosol (Fig. 4A ) and skeletal muscle actin (Fig. 4B) , these proteins were enzymatically active. By contrast, E428Q, E430Q, S388A, and R345K mutants of CDTa showed no or significantly reduced labeling of actin, indicating that these mutants had no or largely reduced ADP-ribosyltransferase activity. To test the CDTa mutant proteins in more detail, a time course study of the ADP-ribosylation of actin from platelet cytosol (Fig. 5A ) and of actin from rabbit skeletal muscle (Fig. 5B) was performed.
Cytotoxic effects of rCDTa and mutant proteins on Vero cells. Next, we tested whether the various recombinant CDTa proteins caused a breakdown of the actin cytoskeleton in Vero cells. The binding component of iota toxin, Ib, was used to deliver CDTa into the cells. Subconfluently growing Vero cells were incubated with Ib (300 ng/ml) together with the CDTa protein (200 ng/ml) in complete medium at 37°C. For controls, cells were treated without any toxin, with Ib alone, or with the various CDTa proteins alone. After 4.5 h, pictures were taken (Fig. 6) . The CDTa proteins (200 ng/ml) which were active in the in vitro ADP-ribosylation assay were also able to induce cell rounding in the presence of Ib. By contrast, Ib plus the CDTa mutant proteins E428Q, E430Q, S388A, and R345K did not cause cell rounding, even when they were added at a higher concentration (1 g/ml). Ib alone and the CDTa proteins alone had no effect on cell morphology. To confirm that cell rounding was caused by ADP-ribosylation of cellular actin, cells were incubated with Ib together with rCDTa and each CDTa mutant protein. [ 32 P]NAD. Actin from cells which were intoxicated with active CDTa was already ADP-ribosylated and did not serve as a substrate for radiolabeling. In Fig. 7 the autoradiogram of labeled actin is shown. The actin from cells which were rounded up after toxin treatment was only weakly labeled, whereas the actin from cells which were previously treated with the CDTa mutant proteins E428Q, E430Q, S388A, and R345K showed strong actin labeling.
In vitro ADP-ribosyltransferase activity of CDTa 244-463 . The catalytic center of the CDTa appears to be located at the C-terminal part of the protein. We tested whether the C terminus of CDTa represents a functionally independent domain carrying an ADP-ribosyltransferase activity. An N-terminally truncated fragment, CDTa 244-463 , was constructed and expressed in E. coli. Figure 8A shows the stained recombinant CDTa and CDTa 244-463 proteins after cleavage with thrombin and SDS-PAGE. Both proteins were tested in an in vitro ADPribosylation assay with actin from platelet cytosol (Fig. 8B) and from rabbit skeletal muscle (Fig. 8C) . In the presence of either actin substrate, the fragment CDTa 244-463 was much less active than the full-length CDTa protein.
Enzymatic activities and substrate specificities of CDTa, Ia, and C2I. The iota-like toxins CDTa and Ia both ADP-ribosylate ␤/␥-nonmuscle actin as well as ␣-actin isoforms (24) . By   FIG. 3 . SDS-PAGE and immunoblot analysis of mutant CDTa proteins. CDTa proteins were expressed in E. coli as GST fusion proteins and purified as described in the text. Proteins (500 ng of each) were subjected to SDS-12.5% PAGE and stained with Coomassie blue (A) or blotted onto nitrocellulose and detected with an antiserum against C. spiroforme ADP-ribosyltransferase and peroxidase-coupled protein A (B). Lanes 1, rCDTa; lanes 2, E428Q; lanes 3, E430Q; lanes 4, S388A; lanes 5, T389V; lanes 6, S390A; lanes 7, R345K; lanes 8, R346K. contrast, C2I accepts ␤/␥-actin but not ␣-actin isoforms as a substrate (16) . Because the enzyme activity of CDTa 244-463 was reduced compared to that of the full-length protein, we tested various C-terminal fragments of Ia and C2I for their ADPribosyltransferase activities. Various fragments of Ia and C2I were constructed and expressed as GST fusion proteins. For Ia (413 amino acid residues), the fragments GST-Ia 101-413 , GST-Ia 177-413 , GST-Ia 208-413 , and GST-Ia 270-413 were purified and analyzed by SDS-PAGE (Fig. 9A) . These fragments and GST-Ia were used for in vitro ADP-ribosylation of platelet cytosol. The autoradiogram of 32 P-labeled actin is shown in Fig. 9B . GST-Ia, GST-Ia , GST-Ia , and GST-Ia were enzymatically active, but the fragment GST-Ia 270-413 did not ADP-ribosylate actin. Similar results were obtained when thrombin-cleaved Ia was used instead of GST-Ia (not shown).
Next, we tested the C-terminal domain of C2I for ADPribosyltransferase activity. Because C2I 226-431 was enzymatically inactive, we made further C2I truncations to test which part of the N terminus of this protein can be removed without a loss of ADP-ribosyltransferase activity. All of these N-terminally truncated C2I fragments (C2I 103-431 and C2I 190-431 ) were enzymatically inactive, including the fragment C2I 30-431 (not shown). CDTa 1-240 mediates the interaction of CDTa with Ib. To study the function of the N-terminal domain of CDTa, we expressed the C-terminally truncated CDTa 1-240 fragment (amino acids 1 to 240) in E. coli and tested its ability to interact with activated Ib by performing a competition assay with CDTa. Vero cells were incubated with Ib or CDTa in the presence of a 400-fold excess of CDTa . As shown in Fig.  10 , after an 8-h incubation period, fewer cells were rounded up after treatment with CDTa plus Ib in the presence of CDTa than after treatment with CDTa plus Ib. To exclude any nonspecific effects caused by the large amount of CDTa , bovine serum albumin (BSA) and C3 transferase from Clostridium limosum were tested for inhibition of cytotoxic effects induced by CDTa plus Ib. Vero cells were incubated with Ib and CDTa in the presence of BSA (120 g/ml) or C3 transferase (120 g/ml). Neither BSA nor C3 transferase showed any effect on the intoxication of the cells by CDTa plus Ib (not shown). This observation suggests that the competition of CDTa with CDTa was specific and that the N-terminal domain of CDTa interacts with Ib.
DISCUSSION
Here, we characterized the actin ADP-ribosyltransferase CDTa from C. difficile. CDT is a member of the iota family of binary ADP-ribosylating toxins, which also includes iota toxin from C. perfringens and the ADP-ribosyltransferase from C. spiroforme (3, 5, 20, 21, 25) . The enzymatic components of these proteins (CDTa, Ia, and Sa) show high sequence homology to the enzymatic component of the C2 toxin from C. botulinum and to VIP2, the enzymatic component of the vegetative insecticidal protein (VIP) from Bacillus cereus. Although it has been directly shown only for C2 toxin (28) and iota toxin (27) , all of these proteins are suggested to ADP- ribosylate G-actin at Arg177 to block actin polymerization and to induce the breakdown of the actin cytoskeleton (1) .
The ADP-ribosyltransferases C2I, Ia, and CDTa are composed of N-and C-terminal domains which divide the proteins into two sections of similar size. Han et al. reported for the enzyme component (VIP2) of the related VIP toxin that the Nand C-terminal domains share the same topology (13) and may have developed by duplication from a common ancestral ADPribosyltransferase gene. We were interested in studying whether the N-and C-terminal parts of ADP-ribosyltransferases represent functionally independent domains that possess adapter and/or enzyme activities when expressed as separated fragments. Our studies with CDTa revealed that the N-terminal part of the binary ADP-ribosyltransferases is involved in the interaction with the binding component. For C2I, we showed previously that the N terminus (amino acid residues 1 to 225), which is enzymatically inactive, binds to the C2II binding component and mediates uptake of C2I as well as that of the C2I -C3 fusion toxin (6) . Even the truncation C2I , consisting of amino acid residues 1 to 87, was able to mediate uptake of the C3 fusion toxin into cells (H. Barth et al., submitted for publication). This strongly suggests that the N-terminal part of C2I represents a functional domain which interacts with C2II. Also, the N terminus of CDTa acts as an adapter and mediates the interaction of the enzyme component with the binding component. Here, we report that the N-terminal domain of CDTa (amino acids 1 to 240) competed with full-length CDTa for the binding component. In our experiments, we used Ib, the binding component of the iota toxin, to deliver CDTa into cells, because the native CDTb binding component was not well expressed as a recombinant protein in E. coli.
The catalytic sites of Ia and C2I, which are located within the C-terminal part of the proteins, were previously characterized in detail. In the enzyme component Ia of C. perfringens iota toxin, Glu380 was identified as the catalytic glutamate that is essential for enzyme activity (18) . For the enzyme component C2I of C. botulinum C2 toxin, we reported earlier that Glu387, Glu389, Ser348, and Arg299 are essential for ADP-ribosyltransferase activity, with Glu389 being the catalytic glutamic acid residue (8) . In the present study, we show that the equivalent amino acid residues in CDTa are E428, E430, S388, and R345. Mutation of one of these residues inhibited or reduced the enzyme activity of CDTa and prevented intoxication of cells. As deduced from the crystal structure analysis of the related VIP2, the catalytic glutamic acid residue of CDTa (E430) is most likely involved in stabilization of the oxocarbenium transition state by forming a hydrogen bond with the 2Ј-hydroxyl group of the nicotinamide ribose. Glu428, which is equivalent to Glu426 of VIP2, is suggested to participate in the interaction with the incoming substrate and increases the nucleophilicity of the ADP-ribose acceptor amino acid residue Arg177 of actin. Ser388 is part of the STS motif and is probably involved in stabilization of the NAD-binding pocket. Similarly, Arg345 is likely to be involved in NAD binding (13) .
We tested whether the C-terminal domains of the actin ADP-ribosylating toxins CDTa, Ia, and C2I were enzymatically active when they were expressed without their N-terminal parts. Whereas the enzyme domain of iota toxin was fully active compared to the full-length enzyme, CDTa 244-463 was markedly less active than the full-length protein. Skeletal muscle actin was less effectively ADP-ribosylated by the CDTa 244-463 fragment than cytosolic actin from platelets. One reason might be that nonmuscle actin is a preferred substrate for the toxin. However, it is also plausible that the presence of additional proteins in the cytosolic preparation which prevent polymerization of G-actin to F-actin facilitates ADP-ribosylation, because G-actin but not F-actin is a substrate for ADPribosylation (1, 27, 28) .
All N-terminally truncated C2I fragments tested were unable to catalyze ADP-ribosylation of actin. Surprisingly, even C2I 30-431 , from which amino acid residues 1 to 29 were deleted, did not exhibit ADP-ribosyltransferase activity at all. We suggest that amino acid residues 1 to 29 of C2I are necessary for proper folding of the C-terminal part of this enzyme. Thus, although various conserved amino acid residues that may be similarly involved in the enzyme activity of the toxins could be identified, the various actin ADP-ribosylating toxins appear to differ in their minimal structural requirements for proper folding and/or stability.
So far the clinical relevance and pathogenetic role of the actin ADP-ribosylating toxin CDTa are not clear. Only about 7 to 12.5% of clinical isolates contain CDT (20, 26) . Diseases induced by C. difficile differ greatly in severity. The spectrum includes mild and trivial diarrhea, pseudomembranous colitis, toxic megacolon, and even fulminant life-threatening colitis. Because CDT is, like other actin ADP-ribosylating toxins, a highly potent cytotoxin, it is plausible that damage of the mucosal barrier function by CDT prepares the way for the action of typical clostridial cytotoxins. Thus, it remains to be clarified whether CDTa plays a specific role in one of the severe clinical manifestations induced by C. difficile.
